RxDoctor Payments DataLook up a doctor →

Aamer Habib, MD

Neurology · Champaign, ILNPI 1922128560

Payments from drug & device makers

$377,481in general payments, 2019–2025

Across 450 payments — averaging $838.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$368K
  • AbbVie$935
  • Supernus Pharmaceuticals, Inc.$611
  • Lilly USA, LLC$587
  • Genentech USA, Inc.$471
  • Novartis$419
  • plus $7K from 52 others

What the payments were for

  • Food & beverage$9,20197%
  • Education$2753%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly2$367,928
AbbVie(2 entities)66$935
Supernus Pharmaceuticals, Inc.10$611
Lilly USA, LLC28$587
Genentech USA, Inc.21$471
Novartis25$419
Catalyst Pharmaceuticals, Inc.16$405
Lundbeck LLC12$396
Biogen19$351
Teva Pharmaceuticals USA, Inc.13$347
AstraZeneca13$339
Eisai Inc.13$321
Amgen12$318
Pfizer20$306
UCB, Inc.12$290
SK Life Science, Inc.9$267
Bristol Myers Squibb22$235
Grifols USA, LLC10$235
Amneal Pharmaceuticals LLC13$224
Neurocrine Biosciences, Inc.11$220
MDD US Operations, LLC6$164
Acadia Pharmaceuticals Inc8$144
Axsome Therapeutics, Inc.6$139
Jazz Pharmaceuticals Inc.4$117
Merz Pharmaceuticals, LLC4$111
Takeda Pharmaceuticals U.S.A., Inc.4$106
Sumitomo Pharma America, Inc.6$103
Biohaven Pharmaceutical Holding Company Ltd.5$102
Sunovion Pharmaceuticals Inc.6$92
EMD Serono, Inc.5$90
Impel Pharmaceuticals Inc.3$87
Greenwich Biosciences, Inc.1$83
Tanabe Pharma America, Inc.3$74
Banner Life Sciences, LLC3$72
Octapharma USA, Inc.2$67
Avion Pharmaceuticals4$66
Johnson & Johnson3$60
Kyowa Kirin, Inc.3$59
Abbott3$56
Argenx US, Inc.2$45
Sanofi2$41
Adamas Pharmaceuticals, Inc.2$35
Ipsen Biopharmaceuticals, Inc2$34
Inspire Medical Systems, Inc.1$33
GE HealthCare1$31
E.r. Squibb & Sons, L.L.C.2$30
Otsuka America Pharmaceutical, Inc.1$26
TG Therapeutics, Inc.1$24
Neuronetics, Inc.1$24
Bayer1$24
Cycle Pharmaceuticals Inc1$21
Saol Therapeutics Inc.1$20
Xeris Pharmaceuticals, Inc.1$19
Acorda Therapeutics, Inc1$19
Idorsia Pharmaceuticals US Inc1$17
Promius Pharma LLC1$15
Harmony Biosciences LLC1$13
Assertio Therapeutics, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$377,481 in reported general payments places this provider in the 95th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$355,090
Medicare patients
413
Services billed
19,874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate14$118,942
NuplazidPimavanserin Tartrate17$87,731
BafiertamMonomethyl Fumarate11$69,892
Nurtec OdtRimegepant Sulfate30$42,839
Aimovig AutoinjectorErenumab-Aooe40$29,949
Carbidopa-LevodopaCarbidopa/Levodopa419$17,226
Clobazam24$11,084
Memantine Hcl366$8,913
Dalfampridine ErDalfampridine30$8,763
Pregabalin193$8,758
Carbidopa-Levodopa ErCarbidopa/Levodopa33$7,926
Lacosamide45$6,405
Gabapentin290$5,435
Levetiracetam188$5,308
Baclofen130$3,697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$220$118,94214 claims
Acadia Pharmaceuticals IncNuplazid$144$87,73117 claims
PfizerNurtec Odt$306$42,83930 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$224$2,13824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 neurology providers in Illinois.

Other neurology in Champaign

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →